Results 101 to 110 of about 33,833,464 (200)

SYNTHETIC DOSAGE LETHAL INTERACTIONS OF POLO-LIKE KINASE 1 AND THEIR APPLICATION IN CANCER THERAPEUTICS [PDF]

open access: yes, 2020
Targeted therapies are crucial for personalizing cancer treatment, but tumour heterogeneity presents a challenge in the identification of effective targets.
Cunningham, Chelsea E
core  

Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1.

open access: yesPLoS ONE, 2013
BackgroundOver the years, a great deal of effort has been focused on the design and synthesis of potent, linear peptide inhibitors targeting the polo-like kinase 1 (Plk1), which is critically involved in multiple mitotic processes and has been ...
Ravichandran N Murugan   +11 more
doaj   +1 more source

Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells

open access: yes
This study investigated Polo-like kinase 1, a mitotic regulator often over-expressed in solid tumors and adult hematopoietic malignancies, as a potential new target in the treatment of pediatric acute lymphoblastic leukemia.
Caron HN   +8 more
core   +4 more sources

On the regulation of chromosome segregation in human cells : implications of Bub1 Kinase inhibition during cell division [PDF]

open access: yes, 2015
The maintenance of correct chromosome number (euploidy) during cell division is essential for health. Loss of euploidy is observed in most cancers and is linked to tumorigenesis.
Baron, Anna
core   +1 more source

Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer.

open access: yesPLoS ONE, 2015
BackgroundHuman polo-like kinase 1 (PLK1) expression has been associated with inferior outcomes in colorectal cancer. Our aims were to analyse PLK1 in rectal cancer, and its association with clinicopathological variables, overall survival as well as ...
T G Tut   +8 more
doaj   +1 more source

Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition

open access: yes, 2014
The deregulation of Polo-like kinase 1 is inversely linked to the prognosis of patients with diverse human tumors. Targeting Polo-like kinase 1 has been widely considered as one of the most promising strategies for molecular anticancer therapy. While the
Yuan, Juping   +3 more
core   +1 more source

Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition

open access: yesFrontiers in Bioscience-Landmark
Background: Lung cancer remains a major global public health challenge, with lung adenocarcinoma being the most prevalent histologic subtype.
Jie Yin   +13 more
doaj   +1 more source

PLK1 inhibition delays mitotic entry revealing changes to the phosphoproteome of mammalian cells early in division

open access: yesThe EMBO Journal
Polo-like kinase 1 (PLK1) is a conserved regulator of cell division. During mitotic prophase, PLK1 contributes to the activation of the cyclin-dependent kinase 1 (CDK1).
Monica Gobran   +5 more
doaj   +1 more source

CRL4 DCAF1 ubiquitin ligase regulates PLK4 protein levels to prevent premature centriole duplication

open access: yesLife Science Alliance
This study identifies the E3 ubiquitin ligase, CRL4DCAF1, as a new regulator of polo-like kinase 4, PLK4, protein levels in the G2 phase of the cell cycle to prevent premature duplication of centrioles.
Josina Grossmann   +4 more
doaj   +1 more source

Purification and Cloning of a Protein Kinase That Phosphorylates and Activates the Polo-Like Kinase Plx1

open access: yes, 1998
The Xenopus polo-like kinase 1 (Plx1) is essential during mitosis for the activation of Cdc25C, for spindle assembly, and for cyclin B degradation.
Eleanor Erikson   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy